MDR1 gene polymorphisms and response to acute risperidone treatment

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 2, 2010, Pages 387-392

  Kastelic, Matej ^a   Koprivsek Jure J ^b   Plesnišar, Blanka Kores ^c   Serretti, Alessandro ^d   Mandelli, Laura ^d   Locatelli, Igor ^a   Grabnar, Iztok ^a   Dolzan Vita V ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^c University Clinical Hospital Ljubljana   (Slovenia)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Adverse effects; Antipsychotics; Pharmacogenetics; Schizophrenia; Treatment response

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; PALIPERIDONE; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; BODY MASS; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENE DOSAGE; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PARKINSONISM; RISK FACTOR; SCHIZOPHRENIA; STEADY STATE;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SLOVENIA; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 77649271034     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.01.005     Document Type: Article

References (54)

1. Alenius M., Wadelius M., Dahl M.L., Hartvig P., Lindstrom L., Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res 2008, 42:884-893.
2. American Psychiatric Association Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association. American Journal of Psychiatry 1994, 151:1-36.
3. Aravagiri M., Yuwiler A., Marder S.R. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology (Berl) 1998, 139:356-363.
4. Barnes T.R. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-676.
5. Basic S., Hajnsek S., Bozina N., Filipcic I., Sporis D., Mislov D., et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 2008, 17:524-530.
6. Begley D.J. ABC transporters and the blood-brain barrier. Curr Pharm Des 2004, 10:1295-1312.
7. Bohanec Grabar P., Logar D., Lestan B., Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 2008, 64:1057-1068.
8. Boulton D.W., DeVane C.L., Liston H.L., Markowitz J.S. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002, 71:163-169.
9. Bozina N., Kuzman M.R., Medved V., Jovanovic N., Sertic J., Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 2008, 42:89-97.
10. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001, 69:169-174.
11. Chinn L.W., Kroetz D.L. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 2007, 81:265-269.
12. Cohen J. Statistical power analysis for the behavioral sciences 1988, Lawrence Erlbaum Associates, Hillsdale, New Jersey.
13. Ebinger M., Uhr M. ABC drug transporter at the blood-brain barrier: effects on drug metabolism and drug response. Eur Arch Psychiatry Clin Neurosci 2006, 256:294-298.
14. Fang J., Gorrod J.W. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol 1999, 19:491-510.
15. Faul F., Erdfelder E., Lang A.G., Buchner A. GPower 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007, 39:175-191.
16. Fromm M.F. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000, 38:69-74.
17. Guy W. ECDEU Assessment manual for psychopharmacology: revised. 76-338 DPNA, editor.; Rockville, MD. 1976.
18. Huang M.L., Van Peer A., Woestenborghs R., De Coster R., Heykants J., Jansen A.A., et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993, 54:257-268.
19. Ieiri I., Takane H., Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004, 43:553-576.
20. Kakihara S., Yoshimura R., Shinkai K., Matsumoto C., Goto M., Kaji K., et al. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005, 20:71-78.
21. Kendler K.S. "A gene for...": the nature of gene action in psychiatric disorders. Am J Psychiatry 2005, 162:1243-1252.
22. Kurzawski M., Pawlik A., Gornik W., Drozdzik M. Frequency of common MDR1 gene variants in a Polish population. Pharmacol Rep 2006, 58:35-40.
23. Kwan P., Baum L., Wong V., Ng P.W., Lui C.H., Sin N.C., et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav 2007, 11:112-117.
24. Locatelli I., Mrhar A., Grabnar I. Simultaneous determination of risperidone and 9-hydroxyrisperidone enantiomers in human blood plasma by liquid chromatography with electrochemical detection. J Pharm Biomed Anal 2009, 50:905-910.
25. Mahar Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 2002, 303:1029-1037.
26. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
27. Mosyagin I., Runge U., Schroeder H.W., Dazert E., Vogelgesang S., Siegmund W., et al. Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia 2008, 49:1555-1561.
28. Nasrallah H.A., Mulvihill T. Disorders associated with conventional vs. atypical antipsychotics. Ann Clin Psychiatry 2001, 13:215-227.
29. Prior T.I., Baker G.B. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003, 28:99-112.
30. Riedel M., Schwarz M.J., Strassnig M., Spellmann I., Muller-Arends A., Weber K., et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 2005, 255:261-268.
31. Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction?. Drug Metab Pharmacokinet 2005, 20:391-414.
32. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003, 55:3-29.
33. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A., van Deemter L., Smit J.J., et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 1997, 94:4028-4033.
34. Scordo M.G., Spina E., Facciola G., Avenoso A., Johansson I., Dahl M.L. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999, 147:300-305.
35. Serretti A., De Ronchi D., Lorenzi C., Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem 2004, 11:343-358.
36. Shinkai T., De Luca V., Utsunomiya K., Sakata S., Inoue Y., Fukunaka Y., et al. Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia. Neuromolecular Med 2008, 10:362-367.
37. Siddiqui A., Kerb R., Weale M.E., Brinkmann U., Smith A., Goldstein D.B., et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003, 348:1442-1448.
38. Sills G.J., Mohanraj R., Butler E., McCrindle S., Collier L., Wilson E.A., et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 2005, 46:643-647.
39. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
40. Spina E., Avenoso A., Facciola G., Salemi M., Scordo M.G., Ancione M., et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 2001, 153:238-243.
41. Stahl S.M., Grady M.M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004, 11:313-327.
42. Takao T., Tachikawa H., Kawanishi Y., Katano T., Sen B., Homma M., et al. Association of treatment-resistant schizophrenia with the G2677A/T and C3435T polymorphisms in the ATP-binding cassette subfamily B member 1 gene. Psychiatr Genet 2006, 16:47-48.
43. Tamai I., Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000, 89:1371-1388.
44. Tan N.C., Heron S.E., Scheffer I.E., Pelekanos J.T., McMahon J.M., Vears D.F., et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004, 63:1090-1092.
45. Tiilikainen A., Fischer G., Grubic Z., Gyodi E., Ivaskova E., Jungerman M., et al. Anthropological features of the East European region. HLA: genetic diversity of HLA functional and medical implication. Proceedings of the 12th international histocompatibility workshop and conference 1997, 307-313. EDK, Medical and Scientific International Publisher, Paris. D. Charron (Ed.).
46. Tregouet D.A., Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007, 23:1038-1039.
47. Tregouet D.A., Escolano S., Tiret L., Mallet A., Golmard J.L. A new algorithm for haplotype-based association analysis: the stochastic-EM algorithm. Ann Hum Genet 2004, 68:165-177.
48. Ufer M., Mosyagin I., Muhle H., Jacobsen T., Haenisch S., Hasler R., et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics 2009, 19:353-362.
49. Vidan-Jeras B., Jurca B., Dolzan V., Jeras M., Breskvar K., Bohinjec M. Caucasian Slovenian normal. HLA 1998 1998, 180-181. American society for histocompatibility and immunogenetics, Lenexa. D.W. Gjertson, P.I. Terasaki (Eds.).
50. Wijnholds J., deLange E.C., Scheffer G.L., van den Berg D.J., Mol C.A., van der Valk M., et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 2000, 105:279-285.
51. Yasui-Furukori N., Saito M., Nakagami T., Kaneda A., Tateishi T., Kaneko S. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:286-291.
52. Yasui-Furukori N., Tsuchimine S., Saito M., Nakagami T., Sato Y., Kaneko S. Association between major multidrug resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1230-1234.
53. Yasui-Furukori N., Saito M., Nakagami T., Furukori H., Suzuki A., Kondo T., et al. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J Psychopharmacol 2009, [Electronic publication ahead of print].
54. Yoshimura R., Ueda N., Nakamura J. Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology 2001, 44:129-133.